Pfizer Inc. and Astellas Pharma Inc. announced results from the phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer.
Bristol-Myers Squibb Co. announced new results from the phase III CheckMate-214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma.
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery could help prolong their lives.
The black-white gap has closed considerably over the past several decades, a new report finds.
The American Cancer Society Cancer Action Network released a report that report examines the growing burden of cervical cancer in low- and middle-income countries around the world.
Researchers at Georgetown Lombardi Comprehensive Cancer Center released a study that may show immunotherapy offers similar benefit to cancer patients living with HIV.
The first report from a phase II, multi-center clinical trial indicates that a newer, more aggressive form of radiation therapy, stereotactic radiation, can extend long-term survival for some patients with stage-IV cancers while maintaining their quality of life.
Noxopharm announced interim results from the dose-ranging component of the DARRT-1 study. Some of their key findings include combining Veyonda with low-dose radiotherapy applied to a single metastasis is able to produce an anti-cancer response in both the irradiated and non-irradiated lesions as evidenced by PSA response, pain reduction, and/or tumour measurements.
A study in JNCI Cancer Spectrum has identified a connection between prolonged time spent sitting while watching TV and an increased risk of colorectal cancer for younger Americans.
A study now underway aims to better incorporate patient feedback into clinical trials that help determine which new cancer treatments will be approved for use.